23:57:40 (BST) 23:57:40 (BST)
CSE news on BXPHARMA
2024-03-04: Appointment of Managing Director
BXPHARMA: The Board of Directors of the Company has appointed the existing Director Mr. Iqbal Ahmed as the Managing Director of the Company for a period of 5 (Five) years effective from 03.03.2024 to 02.03.2029, subject to the approval of the Shareholders in the next Annual General Meeting (AGM) of the Company.
2024-02-22: Cash Dividend Disbursement
BXPHARMA: The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2023 to the respective shareholders.
2024-01-30: Cont-Un-audited HY A/Cs
BXPHARMA(cont): Reasons for deviation in NOCFPS: Cash outflows for inventories during comparable prior period were notably higher because of strategic buildup of inventories to protect against any supply chain disruption. This, together with improved working capital and revenue growth, resulted in a positive deviation in current period's Operating Cash Flows per share.(end)
2024-01-30: Un-audited HY A/Cs
BXPHARMA: (Quarter 2) As per un-audited half yearly accounts of the company, Consolidated EPS was Tk. 3.21 for October-December 2023 as against Tk. 2.77 for October-December 2022; Consolidated EPS was Tk. 6.69 for July-December 2023 as against Tk. 6.02 for July-December 2022. Consolidated NOCFPS was Tk. 10.01 for July-December 2023 as against Tk. 5.33 for July-December 2022. Consolidated NAV per share was Tk. 101.11 as on December 31, 2023 and Tk. 93.52 as on December 31, 2022.(cont)
2024-01-21: Board Meeting
BXPHARMA: The company has informed that the Board Meeting of the Company will be held on January 29, 2024 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2023.
2024-01-14: Managing Director Resigns to Join Newly Formed Cabinet
BXPHARMA: The company has announced that Mr. Nazmul Hassan MP, the company's Managing Director and Member of the Board, will step down with immediate effect. This follows an invitation from the Prime Minister for Mr. Hassan to join the newly formed Cabinet as a Minister after the recent Bangladesh Parliamentary Election on January 07, 2024.
2023-12-14: Credit Rating
BXPHARMA: Credit Rating Information and Services Limited (CRISL) has rated Beximco Pharmaceuticals Ltd. as ''AAA'' in the long term and ''ST-1'' in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2023 also unaudited financials up to September 30, 2023 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2023-11-12: Record Date tomorrow (13.11.2023)
BXPHARMA: Trading of the shares of Beximco Pharmaceuticals Ltd. will remain suspended on its record date i.e., 13.11.2023. Trading of the shares of the Company will resume on 14.11.2023.
2023-11-08: Spot trade from tomorrow (09.11.2023)
BXPHARMA: Trading of the shares of Beximco Pharmaceuticals Ltd. will be allowed only in the Spot Market from 09.11.2023 to 12.11.2023 as the record date of the Company is on 13.11.2023.
2023-11-06: Un-audited Financial Statements
BXPHARMA: (Quarter 1) As per the un-audited financial statements of the Company, Consolidated EPS was Tk. 3.48 for July-September 2023 as against Tk. 3.24 for July-September 2022; Consolidated NOCFPS was Tk. 6.07 for July-September 2023 as against Tk. 1.53 for July-September 2022. NAV per share was Tk. 101.40 as on September 30, 2023 and Tk. 94.25 as on September 30, 2022. Reasons for deviation in NOCFPS: In the first quarter of comparable prior year, cash out flows for inventories were notably higher because of strategic buildup of inventories to protect against any supply chain disruption. This, together with improved working capital and revenue growth, resulted in a positive deviation in current period's Operating Cash Flows per share.
2023-10-29: Board Meeting
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 05, 2023 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2023.
2023-10-22: CB Free
BXPHARMA: Please note that there will be no price limit today 22.10.2023 on the trading of the shares of the company following its corporate declaration. However, the floor price shall be applicable accordingly.
2023-10-22: Cont-Recommendation of Dividend
BXPHARMA: (Cont) Reasons for deviation in EPS: EPS has been decreased primarily because, during the period July 2021 to June 2022, the company earned a non-recurring pre-tax income of Taka 619 million as Vaccine Distribution Fee under a contractual agreement. As this particular contract has concluded, there has been no income from this source in the current reporting period. Additionally, rising costs, driven by sharp depreciation of BDT against USD and high inflation have further impacted the EPS.(end)
2023-10-22: Recommendation of Dividend
BXPHARMA: The Board of Directors has recommended 35% cash dividend for the year ended June 30, 2023. Date of AGM: 28.12.2023, Time: 10:30 AM, Venue: Digital Platform. Record Date: 13.11.2023. The Company has also reported Consolidated EPS of Tk. 10.34, Consolidated NAV per share of Tk. 97.91 and Consolidated NOCFPS of Tk. 13.64 for the year ended June 30, 2023 as against Consolidated EPS of Tk. 11.48, Consolidated NAV per share of Tk. 91.01 and Consolidated NOCFPS of Tk. 11.69 respectively for the year ended June 30, 2022. (Cont)
2023-10-12: Board Meeting
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on October 19, 2023 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2023.
2023-04-30: Un-audited Financial Statements
BXPHARMA: (Quarter 3) As per un-audited financial statements of Beximco Pharmaceuticals Ltd., Consolidated EPS was Tk. 2.13 for January-March 2023 as against Tk. 2.47 for January-March 2022; Consolidated EPS was Tk. 8.15 for July 2022-March 2023 as against Tk. 9.60 for July 2021-March 2022. Consolidated NOCFPS was Tk. 9.66 for July 2022-March 2023 as against Tk. 8.88 for July 2021-March 2022. Consolidated NAV per share was Tk. 95.65 as on March 31, 2023 and Tk. 89.13 as on March 31, 2022. EPS has been decreased due to increased cost of production and a decrease in gross margin.
2023-04-18: Board Meeting
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on April 29, 2023 at 11:30 AM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2023.
2023-04-10: Sale and Buy confirmations
BXPHARMA: IFIC Securities Limited, one of the Corporate Directors of Beximco Pharmaceuticals Ltd., has further informed that it has completed its sale of 40,00,000 shares whereas New Dacca Industries Limited, another Corporate Director of the company, has also informed that it has completed its buying of 40,00,000 shares through Dhaka Stock Exchange Limited as per declaration disseminated on 05.04.2023.
2023-04-05: Sale and Buy Intention
BXPHARMA: IFIC Securities Limited, one of the Corporate Directors of Beximco Pharmaceuticals Ltd., has reported its intention to sell 40,00,000 shares (in the Block Market) whereas New Dacca Industries Limited, another Corporate Director of the company, has reported its intention to buy 40,00,000 shares (in the Block Market) at prevailing market price through Dhaka Stock Exchange Limited within next 30 working days.
2023-03-27: Sale and Buy confirmations
BXPHARMA: IFIC Securities Limited, one of the Corporate Directors of Beximco Pharmaceuticals Ltd., has further informed that it has completed its sale of 1,70,00,000 shares whereas Absolute Construction & Engineering Ltd., another Corporate Director of the company, has also informed that it has completed its buying of 1,70,00,000 shares through Dhaka Stock Exchange Limited as per declaration disseminated on 13.03.2023.
2023-03-13: Sale and Buy Intention
BXPHARMA: IFIC Securities Limited, one of the Corporate Directors of Beximco Pharmaceuticals Ltd., has reported its intention to sell 1,70,00,000 shares (in the Block Market) whereas Absolute Construction & Engineering Ltd., another Corporate Director of the company, has reported its intention to buy 1,70,00,000 shares (in the Block Market) at prevailing market price through Dhaka Stock Exchange within next 30 working days.
2023-01-30: Cont-Un-audited HY A/Cs
BXPHARMA(cont): as Vaccine Distribution Fee from the distribution of Oxford/AstraZeneca COVID-19 vaccine under a tripartite agreement between the Serum Institute of India (SII), Government of Bangladesh (GOB) and BEXIMCO Pharma. With the end of the contract, there has been no income from this source in the reporting period. NOCFPS has declined due to increased working capital investment consequent to the record devaluation of Taka, increased price of materials and higher domestic inflation. Moreover, the Company needed to maintain additional inventory to protect against any supply chain disruption and to support the organic business growth.(end)
2023-01-30: Un-audited HY A/Cs
BXPHARMA: (Quarter 2) As per un-audited half yearly accounts of Beximco Pharmaceuticals Ltd., Consolidated EPS was Tk. 2.77 for October-December 2022 as against Tk. 3.84 for October-December 2021; Consolidated EPS was Tk. 6.02 for July-December 2022 as against Tk. 7.12 for July-December 2021. Consolidated NOCFPS was Tk. 5.33 for July-December 2022 as against Tk. 8.22 for July-December 2021. Consolidated NAV per share was Tk. 93.52 as on December 31, 2022 and Tk. 86.65 as on December 31, 2021. Reasons for deviation in EPS and NOCFPS: EPS has declined due to increased cost of production and a consequent decrease in gross margin. Moreover, during July-December 2021 period, the Company earned a net amount of BDT 619.00 million(cont)
2023-01-23: Board Meeting
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 29, 2023 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2022.
2023-01-19: Cash Dividend Disbursement
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that it has disbursed the cash dividend for the year ended on June 30, 2022 to the respective shareholders' Bank Accounts through BEFTN system.
2022-12-14: Credit Rating
BXPHARMA: Credit Rating Information and Services Limited (CRISL) has rated Beximco Pharmaceuticals Ltd. as ''AAA'' in the long term and ''ST-1'' in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2022, unaudited financials up to September 30, 2022 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2022-11-20: Record Date tomorrow (21.11.2022)
BXPHARMA: Trading of the shares of Beximco Pharmaceuticals Ltd. will remain suspended on its record date i.e., 21.11.2022. Trading of the shares of the Company will resume on 22.11.2022.
2022-11-16: Spot trade from tomorrow (17.11.2022)
BXPHARMA: Trading of the shares of Beximco Pharmaceuticals Ltd. will be allowed only in the Spot Market from 17.11.2022 to 20.11.2022 as the record date of the Company is on 21.11.2022.
2022-11-13: Cont-Un-audited Financial Statements
BXPHARMA: (Quarter 1) (cont) Net Operating Cash Flow per share declined as against comparable prior period due to increased working capital investment consequent to the record devaluation of Taka, increased price of materials and higher domestic inflation.(end)
2022-11-13: Un-audited Financial Statements
BXPHARMA: (Quarter 1) As per un-audited financial statements of Beximco Pharmaceuticals Ltd., Consolidated EPS was Tk. 3.24 for July-September 2022 as against Tk. 3.28 for July-September 2021; Consolidated NOCFPS was Tk. 1.53 for July-September 2022 as against Tk. 4.46 for July-September 2021. NAV per share was Tk. 94.25 as on September 30, 2022 and Tk. 86.31 as on September 30, 2021. Reasons for significant deviation: Consolidated Earnings Per Share (EPS) for the period July-September 2022 has declined due to decreased EPS of the subsidiary Nuvista Pharma and loss incurred by the other newly acquired subsidiary Synovia Pharma. (cont)
2022-11-03: Board Meeting
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 10, 2022 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2022.
2022-10-30: CB Free
BXPHARMA: Please note that there will be no price limit today 30.10.2022 on the trading of the shares of the company following its corporate declaration, however, as per the BSEC Order No. BSEC/CMRRCD/2001-07/39 dated July 28, 2022, the floor price shall be applicable accordingly.
2022-10-30: Recommendation of Dividend
BXPHARMA: The Board of Directors has recommended 35% cash dividend for the year ended June 30, 2022. Date of AGM: 22.12.2022, Time: 10:30 AM, Venue: Digital Platform. Record Date: 21.11.2022. The Company has also reported consolidated EPS of Tk. 11.48, consolidated NAV per share of Tk. 91.01 and consolidated NOCFPS of Tk. 11.69 for the year ended June 30, 2022 as against Tk. 11.49, Tk. 83.01 and Tk. 13.50 respectively for the same period of the previous year.
2022-10-19: Board Meeting
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on October 27, 2022 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2022.
2022-04-28: Un-audited Financial Statements
BXPHARMA: (Quarter 3) As per un-audited financial statements of Beximco Pharmaceuticals Ltd., Consolidated EPS was Tk. 2.47 for January-March 2022 as against Tk. 3.28 for January-March 2021; Consolidated EPS was Tk. 9.60 for July 2021-March 2022 as against Tk. 8.23 for July 2020-March 2021. Consolidated NOCFPS was Tk. 8.88 for July 2021-March 2022 as against Tk. 9.05 for July 2020-March 2021. Consolidated NAV per share was Tk. 89.13 as on March 31, 2022 and Tk. 79.73 as on March 31, 2021.
2022-04-21: Board Meeting
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on April 27, 2022 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2022.
2022-01-30: Cont-Un-audited HY A/Cs
BXPHARMA: (Quarter 2) (Cont) The company achieved over 17% growth in consolidated sales as compared to prior period. Moreover, other income also increased predominantly due to income from vaccine distribution fee which was not there in the comparative prior period. These have contributed towards increase in consolidated earning per share. Consolidated operating cash flow per share also increased due to higher revenue and improved net working capital.(end)
2022-01-30: Un-audited HY A/Cs
BXPHARMA: (Quarter 2) As per un-audited half yearly accounts of Beximco Pharmaceuticals Ltd., Consolidated EPS was Tk. 3.84 for October-December 2021 as against Tk. 2.54 for October-December 2020; Consolidated EPS was Tk. 7.12 for July-December 2021 as against Tk. 4.95 for July-December 2020. Consolidated NOCFPS was Tk. 8.22 for July-December 2021 as against Tk. 4.91 for July-December 2020. Consolidated NAV per share was Tk. 86.65 as on December 31, 2021 and Tk. 76.45 as on December 31, 2020. (Cont)
2022-01-23: Board Meeting
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 27, 2022 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2021.
2022-01-20: Cash Dividend Disbursement
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that it has disbursed the cash dividend for the year ended on June 30, 2021 to the respective shareholders' Bank Accounts through BEFTN system.
2021-12-19: Credit Rating
BXPHARMA: Credit Rating Information and Services Limited (CRISL) has rated Beximco Pharmaceuticals Ltd. as ''AAA'' in the long term and ''ST-1'' in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2021, also unaudited financials up to September 30, 2021 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2021-11-21: Record Date tomorrow (22.11.2021)
BXPHARMA: Trading of the shares of Beximco Pharmaceuticals Ltd. will remain suspended on its record date i.e., 22.11.2021. Trading of the shares of the Company will resume on 23.11.2021.
2021-11-17: Spot trade from tomorrow (18.11.2021)
BXPHARMA: Trading of the shares of Beximco Pharmaceuticals Ltd. will be allowed only in the Spot Market from 18.11.2021 to 21.11.2021 as the record date of the Company is on 22.11.2021.
2021-11-14: Cont-Un-audited Financial Statements
BXPHARMA: (Quarter 1) (Cont) Alongside gaining from the double-digit sales growth consistent to past p increase in sales in the reported first quarter as compared to the same period of prior year. Alongside gaining from the double-digit sales growth consistent to past periods, higher demand for the repurposed drugs for the Covid-19 treatment, other medicines related to the treatment of Covid-19 patients and new products contributed to the attainment of sales growth. The earning per share and operating cash flows per share increased predominantly due to the increase in sales.(end)
2021-11-14: Un-audited Financial Statements
BXPHARMA: (Quarter 1) As per un-audited financial statements of Beximco Pharmaceuticals Ltd., Consolidated EPS was Tk. 3.28 for July-September 2021 as against Tk. 2.41 for July-September 2020; Consolidated NOCFPS was Tk. 4.46 for July-September 2021 as against Tk. 3.00 for July-September 2020. NAV per share was Tk. 86.31 as on September 30, 2021 and Tk. 82.78 as on September 30, 2020. The Company achieved 22.3% increase in sales in the reported first quarter as compared to the same period of prior year.(Cont)
2021-11-07: Board Meeting
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 11, 2021 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2021.
2021-10-24: CB Free
BXPHARMA: Please note that there will be no price limit today 24.10.2021 on the trading of the shares of the Company following its corporate declaration.
2021-10-24: Recommendation of Dividend
BXPHARMA: The Board of Directors has recommended 35% cash dividend for the year ended on June 30, 2021. Date of AGM: 23.12.2021, Time: 10:30 AM, Venue: Digital Platform. Record Date: 22.11.2021. The Company has also reported Consolidated EPS of Tk. 11.49, Consolidated NAV per share of Tk. 83.01 and Consolidated NOCFPS of Tk. 13.50 for the year ended on June 30, 2021 as against Tk. 7.88, Tk. 80.12 and Tk. 13.67 respectively for the same period of the previous year.
2021-10-12: Board Meeting
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on October 21, 2021 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2021.
2021-10-03: Completion of acquisition of a majority stake in Sanofi Bangladesh Ltd
BXPHARMA: Referring to their earlier news disseminated by CSE on 24.01.2021, 05.09.2021 and 14.09.2021 regarding acquisition of a majority stake in Sanofi Bangladesh Limited, Beximco Pharmaceuticals Ltd. has further informed that they have now completed its acquisition of the majority stake in Sanofi Bangladesh Limited. The final consideration, payable in cash (post the closing adjustments previously outlined), was approximately BDT 469.62 crore (Equivalent pound 39.35 million).
2021-09-15: Cont3-Share Purchase Agreement Signed
BXPHARMA(cont3):In the year ended 31 December 2020 (the last audited accounts prepared by Sanofi Bangladesh), Sanofi Bangladesh generated revenue of Taka 3.038 billion (approximately 25.8 million Pound), profit before tax of Taka 277.6 million (approximately 2.35 million Pound) and had gross assets of Taka 6.409 billion (approximately 54.4m Pound). A further announcement will be made in due course to confirm final completion of the Acquisition.(end)
2021-09-15: Cont2-Share Purchase Agreement Signed
BXPHARMA(cont2):Sanofi Bangladesh has over 800 employees and produces approximately 100 branded generic products, predominately for the local market. Sanofi Bangladesh has a strong presence in cardiology, diabetes, oncology, dermatology and CNS. Sanofi also supplies its global brands of vaccines, insulins and chemotherapy drugs to Bangladesh through direct imports, which the Group will continue to distribute following the completion of the Acquisition. (cont3)
2021-09-15: Cont1-Share Purchase Agreement Signed
BXPHARMA(cont1): Sanofi Bangladesh has been part Sanofi SA ("Sanofi"), a global biopharmaceutical company focused on human health. The operations in Bangladesh were established in 1958 as part of the British chemical company, May & Baker. Following a series of mergers, it became known as Sanofi-Aventis in 2004, before being renamed in 2013 as Sanofi Bangladesh Limited. Sanofi Bangladesh's state-of-the-art manufacturing facilities, including a PICIS certifiable manufacturing facility for the leading antibiotic, cephalosporin, are spread over c25 acres of land, located near Beximco Pharma's manufacturing facility in Tongi.(cont2)
2021-09-15: Share Purchase Agreement Signed
BXPHARMA: Refer to the earlier news disseminated by CSE on 24 January 2021 and 05 September 2021, Beximco Pharmaceuticals Ltd. has further informed that the Company has now entered into the share purchase agreement to acquire the majority stake in Sanofi Bangladesh Limited ("Sanofi Bangladesh") (the "Acquisition"). The proposed earnings accretive Acquisition is in line with Beximco Pharma's strategy to expand its capabilities and product offering into new specialty therapy areas while enabling the Company to consolidate its position as a leading pharmaceutical in Bangladesh by adding an established business with a reputation for high-quality products.(cont1)
2021-09-05: Sanofi Bangladesh acquisition approved by Bangladesh Bank
BXPHARMA: Refer to their earlier news disseminated by CSE on 24.01.2021 regarding proposed acquisition of a majority stake in Sanofi Bangladesh Limited, Beximco Pharmaceuticals Ltd. has further informed that the Company's proposed acquisition of a majority stake in Sanofi Bangladesh Limited (''Sanofi Bangladesh'') has been approved by the Foreign Exchange Investment Department of Bangladesh Bank. As anticipated, the Company and the Vendor will now seek to execute the Share Purchase Agreement. Further announcements will be made in due course.
2021-05-02: Cont-2 Un-audited Financial Statements
BXPHARMA: (Quarter 3)(cont-2) This is non-incurring one off contract and any future earning from this source is dependent on the delivery of the committed quantity of vaccine under the agreement.(end)
2021-05-02: Cont-1 Un-audited Financial Statements
BXPHARMA: (Quarter 3) (cont-1) They also informed that they have entered into a tripartite agreement with the Government of Bangladesh (GOB) and the Serum Institute of India Pvt. Ltd. (SII), for the supply of 30 million doses of Oxford University-AstraZenca SARS-CoV-2 vaccine, AZD1222, in Bangladesh. The Company delivered 5 million vaccines during the reported quarter. As per agreement, the Company is to receive fees for import, storage and delivery of the vaccine to the GOB warehouses across the country. A net amount of BDT. 383.70 million after deduction of related expenses from fees, has been reported as Income from Vaccine Distribution: under the head Other Income.(cont-2)
2021-05-02: Un-audited Financial Statements
BXPHARMA: (Quarter 3) As per un-audited financial statements of Beximco Pharmaceuticals Ltd., Consolidated EPS was Tk. 3.28 for January-March 2021 as against Tk. 2.02 for January-March 2020; Consolidated EPS was Tk. 8.23 for July 2020-March 2021 as against Tk. 5.84 for July 2019-March 2020. Consolidated NOCFPS was Tk. 9.05 for July 2020-March 2021 as against Tk. 9.83 for July 2019-March 2020. Consolidated NAV per share was Tk. 79.73 as on March 31, 2021 and Tk. 77.88 as on March 31, 2020. The company has informed that increased in EPS predominantly from the organic growth of business and hence the profit, part of this attributable to the income from Vaccine distribution and increased cash incentive from export.(cont-1)
2021-04-22: Board Meeting
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on April 29, 2021 at 2:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2021.
2021-01-28: Un-audited HY A/Cs
BXPHARMA: (Quarter 2) As per un-audited half yearly accounts of Beximco Pharmaceuticals Ltd., Consolidated EPS was Tk. 2.54 for October-December 2020 as against Tk. 1.89 for October-December 2019; Consolidated EPS was Tk. 4.95 for July-December 2020 as against Tk. 3.83 for July-December 2019. Consolidated NOCFPS was Tk. 4.91 for July-December 2020 as against Tk. 9.14 for July-December 2019. Consolidated NAV per share was Tk. 76.45 as on December 31, 2020 and Tk. 75.66 as on December 31, 2019.
2021-01-24: Cont3-Proposed acquisition of a majority stake in Sanofi Bangladesh Limited
BXPHARMA(cont3):Sanofi would be able to withdraw in which case the Company's commitment would lapse and the Proposed Transaction would not proceed. Directors believe that Sanofi Bangladesh is a strong strategic fit for Beximco Pharma, with the potential to generate opportunities for long-term value creation for both companies, providing a strong foundation for sustainable growth, as well as enhancing the Company's corporate reputation within the global territories it operates.(end)
2021-01-24: Cont2-Proposed acquisition of a majority stake in Sanofi Bangladesh Limited
BXPHARMA(cont2):The final consideration, which may be up to a maximum of GBP 40 million, would be paid in cash on completion of the Proposed Transaction, from a combination of the Company's own cash resources and additional debt. It is anticipated that the Proposed Transaction will be completed within the next three to nine months. If the Proposed Transaction is not approved by the Foreign Exchange Investment Department of Bangladesh Bank, or has not completed by 20 October 2021,(cont3)
2021-01-24: Cont1-Proposed acquisition of a majority stake in Sanofi Bangladesh Limited
BXPHARMA(cont1): The Proposed Transaction is for a total of 1,963,241 shares, representing approximately 54.6% of Sanofi Bangladesh's total share capital. Beximco Pharma was selected as the preferred bidder in a competitive process. The remaining 45.4% shares in Sanofi Bangladesh is owned by the Government of Bangladesh through Bangladesh Chemical Industries Corporation (approximately 20.0%) and the Ministry of Industries (approximately 25.4%). The base-price consideration of GBP 35.5 million is subject to deduction for the net financial debt and adjustments for short/excess over an agreed normative working capital at the closing date.(cont2)
2021-01-24: Proposed acquisition of a majority stake in Sanofi Bangladesh Limited
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that the Board of Directors of the Company (''Beximco Pharma'' or ''the Company'') in their meeting held on January 21, 2021 at 2:30 PM decided to enter into a binding commitment with Sanofi Group regarding the acquisition of a majority stake in Sanofi Bangladesh Limited (''Sanofi Bangladesh'') for a base-price consideration of circa GBP 35.5 million (Great Britain Pound), to be adjusted as set out below (the ''Proposed Transaction''). The Proposed Transaction is subject to approval by the Foreign Exchange Investment Department of Bangladesh Bank and completing the Share Purchase Agreement.(cont1)
2021-01-18: Board Meeting
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 27, 2021 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2020.
2021-01-18: Cash Dividend Disbursement
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that it has disbursed the cash dividend for the year ended on June 30, 2020 to the respective shareholders' Bank Accounts through BEFTN system.
2020-12-23: Bonus Shares Credited
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that it has credited the Bonus shares for the year ended on June 30, 2020 have already been credited through CDBL to the respective shareholders' BO Accounts on December 23, 2020.
2020-11-24: Record Date tomorrow (25.11.2020)
BXPHARMA: Trading of the shares of Beximco Pharmaceuticals Ltd. will remain suspended on its record date i.e., 25.11.2020. Trading of the shares of the Company will resume on 26.11.2020.
2020-11-22: Spot trade from tomorrow (23.11.2020)
BXPHARMA: Trading of the shares of Beximco Pharmaceuticals Ltd. will be allowed only in the Spot Market from 23.11.2020 to 24.11.2020 as the record date of the Company is on 25.11.2020.
2020-11-15: Un-audited Financial Statements
BXPHARMA: (Quarter 1) As per un-audited financial statements of Beximco Pharmaceuticals Ltd., Consolidated EPS was Tk. 2.65 for July-September 2020 as against Tk. 2.13 for July-September 2019; Consolidated NOCFPS was Tk. 3.00 for July-September 2020 as against Tk. 4.59 for July-September 2019. NAV per share was Tk. 82.78 as on September 30, 2020 and Tk. 75.09 as on September 30, 2019.
2020-11-04: Board Meeting
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 12, 2020 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2020.
2020-11-01: Credit Rating
BXPHARMA: Credit Rating Information and Services Limited (CRISL) has rated Beximco Pharmaceuticals Ltd. as "AAA" in the long term and "ST-1" in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2019, unaudited financials up to March 31, 2020 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2020-11-01: cont-Recommendation of Dividend (Additional Information)
BXPHARMA:(cont) The Bonus Share is declared out of accumulated profit. The Bonus Share is not declared from capital reserve or revaluation reserve or any unrealized gain or out of profit earned prior to incorporation of the Company or through reducing paid up capital or through doing anything so that the post-dividend retained earnings become negative.(end)
2020-11-01: Recommendation of Dividend (Additional Information)
BXPHARMA: In reference to the earlier news regarding Recommendation of Dividend disseminated on 29.10.2020, Beximco Pharmaceuticals Ltd. has further informed that declared Bonus Share along with the Cash Dividend considering its requirements of cash for the ongoing expansion projects and the investment needed in connection with Covid-19 Vaccine for which an exclusive distribution agreement has been signed with Serum Institute of India Pvt. Ltd (SII).(cont)
2020-10-29: CB free
BXPHARMA: Please note that there will be no price limit today 29.10.2020 on the trading of the shares of the Company following its corporate declaration, however, as per the BSEC Order No. BSEC/CMRRCD/2001-07/04 dated March 19, 2020, the floor price shall be applicable accordingly.
2020-10-29: Recommendation of Dividend
BXPHARMA: The Board of Directors has recommended 15% cash and 10% stock dividend for the year ended on June 30, 2020. Date of AGM: 19.12.2020, Time: 10:30 AM, Venue: Digital Platform. Record Date: 25.11.2020. The Company has also reported Consolidated EPS of Tk. 8.67, Consolidated NAV per share of Tk. 80.12 and Consolidated NOCFPS of Tk. 13.67 for the year ended on June 30, 2020 as against Tk. 7.48, Tk. 72.96 and Tk. 7.30 respectively for the same period of the previous year.
2020-10-22: Board Meeting
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on October 28, 2020 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2020.
2020-06-23: Un-audited Financial Statements
BXPHARMA: (Quarter 3) As per un-audited financial statements of Beximco Pharmaceuticals Ltd., Consolidated EPS was Tk. 2.22 for January-March 2020 as against Tk. 1.84 for January-March 2019; Consolidated EPS was Tk. 6.48 for July 2019-March 2020 as against Tk. 5.51 for July 2018-March 2019. Consolidated NOCFPS was Tk. 9.83 for July 2019-March 2020 as against Tk. 6.48 for July 2018-March 2019. Consolidated NAV per share was Tk. 77.88 as on March 31, 2020 and Tk. 70.99 as on March 31, 2019.
2020-06-17: Board Meeting
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on June 22, 2020 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2020.
2020-01-29: Un-audited HY A/Cs
BXPHARMA: (Quarter 2) As per un-audited half yearly accounts of Beximco Pharmaceuticals Ltd., Consolidated EPS was Tk. 2.12 for October-December 2019 as against Tk. 1.81 for October-December 2018; Consolidated EPS was Tk. 4.26 for July-December 2019 as against Tk. 3.67 for July-December 2018. Consolidated NOCFPS was Tk. 9.14 for July-December 2019 as against Tk. 2.10 for July-December 2018. Consolidated NAV per share was Tk. 75.66 as on December 31, 2019 and Tk. 69.15 as on December 31, 2018.
2020-01-21: Board Meeting
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 28, 2020 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2019.
2020-01-20: Cash Dividend Disbursement
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that it has disbursed the cash dividend for the year ended on June 30, 2019 to the respective shareholders' Bank Accounts through BEFTN system.
2019-11-24: Record Date tomorrow (25.11.2019)
BXPHARMA: Trading of the shares of Beximco Pharmaceuticals Ltd. will remain suspended on its record date i.e., 25.11.2019. Trading of the shares of the Company will resume on 26.11.2019.
2019-11-20: Spot trade from tomorrow (21.11.2019)
BXPHARMA: Trading of the shares of Beximco Pharmaceuticals Ltd. will be allowed only in the Spot Market from 21.11.2019 to 24.11.2019 as the record date of the Company is on 25.11.2019.
2019-11-14: Un-audited Financial Statements
BXPHARMA: (Quarter 1) As per un-audited financial statements of Beximco Pharmaceuticals Ltd., Consolidated EPS was Tk. 2.13 for July-September 2019 as against Tk. 1.86 for July-September 2018; Consolidated NOCFPS was Tk. 4.59 for July-September 2019 as against Tk. 1.05 for July-September 2018. NAV per share was Tk. 75.09 as on September 30, 2019 and Tk. 68.59 as on September 30, 2018.
2019-11-06: Board Meeting
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 13, 2019 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2019.
2019-10-29: CB free
BXPHARMA: Please note that there will be no price limit today 29 October 2019 on the trading of shares of the Company following its corporate disclosure.
2019-10-29: Recommendation of Dividend
BXPHARMA: The Board of Directors has recommended 15% cash dividend for the year ended on June 30, 2019. Date of AGM: 21.12.2019, Time: 10:30 AM, Venue: Beximco Industrial Park, Sarabo, Kashimpur, Gazipur. Record Date: 25.11.2019. The Company has also reported Consolidated EPS of Tk. 7.48, Consolidated NAV per share of Tk. 72.96 and Consolidated NOCFPS of Tk. 7.30 for the year ended on June 30, 2019 as against Tk. 6.25, Tk. 66.78 and Tk. 4.49 respectively for the same period of the previous year.
2019-10-21: Board Meeting
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on October 28, 2019 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2019.
2019-10-02: Credit Rating
BXPHARMA: Credit Rating Information and Services Ltd. (CRISL) has informed that the Rating Committee of CRISL has assigned the Rating to BEXIMCO Pharmaceuticals Ltd. as ''AA+'' in the long term and ''ST-1'' in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2018, unaudited financials up to March 31, 2019 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2019-01-31: Un-audited HY A/Cs
BXPHARMA: (Quarter 2) As per un-audited half yearly accounts of Beximco Pharmaceuticals Ltd., Consolidated EPS was Tk. 1.81 for October-December, 2018 as against Tk. 1.66 for October-December, 2017; Consolidated EPS was Tk. 3.67 for July-December, 2018 as against Tk. 3.25 for July-December, 2017. Consolidated NOCFPS was Tk. 2.10 for July-December, 2018 as against Tk. 3.14 for July-December, 2017. Consolidated NAV per share was Tk. 69.15 as on December 31, 2018 and Tk. 63.77 as on December 31, 2017.
2019-01-23: Board Meeting
BXPHARMA: Beximco pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 30, 2019 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2018.
2019-01-21: Cash Dividend Disbursement
BXPHARMA: Beximco Pharmaceuticals Ltd. has informed that it has disbursed the cash dividend for the year ended on June 30, 2018 to the respective shareholders' Bank Accounts through BEFTN system.
2018-11-25: Record Date tomorrow (26.11.2018)
BXPHARMA: Trading of the shares of Beximco Pharmaceuticals Ltd. will remain suspended on its record date i.e., 26.11.2018 for EGM and AGM. Trading of the shares of the Company will resume on 27.11.2018.
2018-11-20: Spot trade from 22.11.2018
BXPHARMA: Trading of the shares of Beximco Pharmaceuticals Ltd. will be allowed only in the Spot Market from 22.11.2018 to 25.11.2018 as the record date of the Company is on 26.11.2018 for AGM & EGM.
2018-11-14: Un-audited Financial Statements
BXPHARMA: (Quarter 1) As per un-audited financial statements of Beximco Pharmaceuticals Ltd., Consolidated EPS was Tk. 1.86 for July-September, 2018 as against Tk. 1.59 for July-September, 2017; Consolidated NOCFPS was Tk. 1.05 for July-September, 2018 as against Tk. 1.56 for July-September, 2017. Consolidated NAV per share was Tk. 68.59 as on September 30, 2018 and Tk. 63.36 as on September 30, 2017. As the Company acquired Nuvista Pharma on 2.4.18, the comparative prior period figures are reported in the consolidated figures.
2018-11-07: Board Meeting
BXPHARMA: Beximco pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 13, 2018 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2018.
2018-10-28: CB Free
BXPHARMA: Please note that there will be no price limit today 28 October 2018 on the trading of shares of Beximco pharmaceuticals Ltd. following its corporate disclosure.
2018-10-28: Recommendation of Dividend
BXPHARMA: BEXIMCO pharmaceuticals Ltd. has recommended 12.50% Cash Dividend for the year ended on 30 June 2018. The Board has also decided hold an EGM to pass Special Resolutions to amend certain Clauses of Memorandum of Associations and Articles of Association of the Company. EGM & AGM will be held on 22 December 2018 at 10:00 AM & 10:30 AM respectively at Bexmico Industrial Park, Sarabo, Kashimpur, Gazipur. Record Date for EGM & AGM is on 26 November 2018. The Company has also reported Consolidated EPS of Tk. 6.25, Consolidated NAV per share of Tk. 66.78 and Consolidated NOCFPS of Tk. 4.49 for the year ended on June 30, 2018.
2018-10-21: Board Meeting
BXPHARMA: Beximco pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on October 25, 2018 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2018.
CSE News
©2024 Chittagong Stock Exchange PLC. All rights reserved.